Press Releases

Date	Title	PDF Version
Oct 06, 2020	Alexion Highlights Promising Pipeline & Distinguished Rare Disease Capabilities at Virtual Investor Day
Sep 25, 2020	ULTOMIRIS® (ravulizumab) Receives Approval in Japan for Atypical Hemolytic Uremic Syndrome (aHUS) in Adults and Children
Sep 21, 2020	Alexion Receives CHMP Positive Opinion for New Advanced Formulation of ULTOMIRIS® (ravulizumab) with Significantly Reduced Infusion Time
Sep 14, 2020	Alexion and Caelum Biosciences Announce Start of Phase 3 Studies of CAEL-101 in AL Amyloidosis
Sep 14, 2020	Alexion to Discuss Key Pipeline Programs at Virtual Investor Day
Sep 09, 2020	Alexion Announces Upcoming Data Presentations at MSVirtual2020, the 8th Joint ACTRIMS – ECTRIMS Meeting
Sep 03, 2020	Alexion to Present at Upcoming Virtual Investor Conferences
Aug 06, 2020	Alexion Announces Appointment of First Chief Diversity Officer
Jul 30, 2020	Alexion Reports Second Quarter 2020 Results
Jul 16, 2020	Alexion to Report Second Quarter 2020 Results on Thursday, July 30, 2020

Search